

## DAFTAR PUSTAKA

- Abbafati, C., Abbas, K.M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., 2020. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 396: 1204–1222. [https://doi.org/10.1016/S0140-6736\(20\)30925-9](https://doi.org/10.1016/S0140-6736(20)30925-9)
- Abboud, A., Januzzi, J. L., 2021. Reverse cardiac remodeling and ARNI therapy. *Curr. Heart Fail. Rep.* 18: 71–83. <https://doi.org/10.1007/s11897-021-00501-6>
- Bauersachs, J., 2021. Heart failure drug treatment: the fantastic four. *Eur. Heart J.* 42: 681–683. <https://doi.org/10.1093/eurheartj/ehaa1012>
- Bhagat, A.A., Greene, S.J., Vaduganathan, M., Fonarow, G.C., Butler, J., 2019. Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization. *JACC Heart Fail.* 7(1): 1-12. <https://doi.org/10.1016/j.jchf.2018.06.011>
- Bhatt, A. S., Varshney, A.S., Nekoui, M., Moscone, A., Cunningham, J.W., Jering, K. S., *et al.*, 2021. Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study. *Eur. J. Heart Fail.* 23(7): 1191–1201. <https://doi.org/10.1002/ejhf.2163>
- Blonde, L., Khunti, K., Harris, S.B., Meizinger, C., Skolnik, N.S., 2018. Interpretation and impact of real world clinical data for the practicing clinician. *Adv. Ther.* 35(11): 1763–1774. <https://doi.org/10.1007/s12325-018-0805-y>
- Cavender, M.A., Steg, P.G., Smith, S.C., Eagle, K., Ohman, E.M., Goto, S., *et al.*, 2015. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. *Circulation* 132: 923–931. <https://doi.org/10.1161/CIRCULATIONAHA.114.01479>
- Chatterjee, N.A., Fifer, M.A., 2011. Heart Failure. In: Lily LS, editor. *Patophysiology of heart disease - A collaborative project of medical students and faculty*. fifth ed. Philadelphia. Lippincott Williams and Wilkins. 216-43.
- Choudhry, N. K., Avorn, J., Glynn, R. J., Antman, E. M., Schneeweiss, S., Toscano, M., *et al.*, 2011. Full coverage for preventive medications after myocardial infarction. *New Engl J Med.* 365 (22) :2088– 2097. <https://doi.org/10.1056/NEJMs1107913>
- Cox, Z., Zalawadiya, S., Simonato, M., Redfors, B., Zhou, Z., *et al.*, 2022. Maximally tolerated guideline directed medical therapy and barriers to optimization in patients with heart failure with reduced ejection fraction: the COAPT trial. *Eur. Heart J.* 43 (2): 975. <https://doi.org/10.1093/eurheartj/ehac544.975>

- Dickstein, K., Cohen-Solal, A., Filippatos, G., 2008. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 29:2388–442. <https://doi.org/10.1093/eurheartj/ehn309>
- Desai, A. S., Maclean, T., Blood, A. J., Bosque-Hamilton, J., Dunning, J., Fischer, C., *et al.*, 2020 Remote optimization of guideline directed medical therapy in patients with heart failure with reduced ejection fraction. *JAMA Cardiol.* 5(12):1430-1434. <https://doi.org/10.1001/jamacardio.2020.3757>
- Dunlay, S.M., Givertz, M.M., Aguilar, D., Allen, L.A., Chan, M., Desai, A.S., *et al.*, 2019. Type 2 diabetes mellitus and heart failure a scientific statement from the American Heart Association and the Heart Failure Society of America, *Circulation.* 140: e294-e324. <https://doi.org/10.1161/CIR.0000000000000691>
- Dunlay, S., Killian, J. M., Roger, V. L., Schulte, P. J., Blecker, S. B., Savitz, S.T., *et al.* 2022. Guideline directed medical therapy in newly diagnosed heart failure with reduced ejection fraction in the community. *J. Card. Fail.* 28(10):1500-1508. <https://doi.org/10.1016/j.cardfail.2022.07.047>
- Felker, G.M., Mann, D.L., 2020. Heart Failure: *Companion to Braunwald's Heart Disease.* fourth ed. Elsevier.
- Ghazi, L., Yamamoto, Y., Riello, R.J., Coronel-Moreno, C., Martin, M., O'Connor, K.D., 2022. Electronic alerts to improve heart failure therapy in outpatient practice: A cluster randomized trial. *J. Am. Coll. Cardiol.* 79(22):2203-2213. <https://doi.org/10.1016/j.jacc.2022.04.004>
- Granger, B. B., Kaltenbach, L. A., Fonarow, G.G., Allen, L. A., Lanfear, D. E., Albert, N. M., *et al.*, 2022. Health system level performance in prescribing guideline directed medical therapy for patients with heart failure with reduced ejection fraction: results from the CONNECT-HF Trial. *J. Card. Fail.* 28:1355-1361. <https://doi.org/10.1016/j.cardfail.2022.03.356>
- Greene, S.J., Butler, J., Albert, N.M., DeVore, A.D., Sharma, P.P., Duffy, C.I., *et al.*, 2018. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. *J. Am. Coll. Cardiol.* 72(4):351-366. <https://doi.org/10.1016/j.jacc.2018.04.070>
- Hadidi, S.E., Darweesh, E., Byrne, S., Bermingham, M., 2018. A tool for assessment of heart failure prescribing quality: A systematic review and meta-analysis. *Pharmacoepidemiol Drug Saf.* 27(7):685-694. <https://doi.org/10.1002/pds.4430>
- Hadidi, S.E., Bazan, N.S., Byrne, S., Darweesh, S., Bermingham, M., 2020. Heart failure prescribing quality at discharge from a critical care unit in Egypt: the impact of multidisciplinary care. *Pharmacy (Basel).* 8(3):159. <https://doi.org/10.3390/pharmacy8030159>

- Harikrishnan, S., Jeemon, P., Ganapathi, S., Agarwal, A., Viswanathan, S., Sreedharan, M., *et al.*, 2020. Five year mortality and readmission rates in patients with heart failure in India: Results from the Trivandrum heart failure registry. *Int. J. Cardiol.* 326: 139-143. [https://doi: 10.1016/j.ijcard.2020.10.012](https://doi.org/10.1016/j.ijcard.2020.10.012)
- Heidenreich, P.A., Bozkurt, B., Aguilar, D., Allen, L.A., Byun, J.J., Colvin, M.M., *et al.*, 2022. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. <https://doi.org/10.1161/CIR.0000000000001063>
- Ho, P. M., Bryson, C. L., Rumsfeld, J. S., 2009. Medication adherence: Its importance in cardiovascular outcomes, *Circulation*. 119 (23): 3028–3035. [https://doi: 10.1161/CIRCULATIONAHA.108.768986](https://doi.org/10.1161/CIRCULATIONAHA.108.768986)
- Hollenberg, M. H., Stevenson, L. M., Ahmad, T., Amin, V.J., Bozkurt, B., Butler, J., *et al.*, 2019. ACC Expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: A report of the American College of cardiology solution set oversight committee. *J. Am. Coll. Cardiol.* 74(15):1966-2011. <https://doi.org/10.1016/j.jacc.2019.08.001>
- Irnizarifka., Arifianto, H., 2021. The comprehensive registry and research on heart failure (CORE-HF): 2 years report from single centre Indonesian heart failure clinic registry. *Acta Cardiol. Indones.* 7(2): 13-22. <https://doi.org/10.22146/jaci.v7i2.2266>
- Jarjour, M., Henri, C., Denus, S., Fortier, A., Bouabdallaoui, N., Nigam, A., *et al.*, 2020. Care gaps in adherence to heart failure guidelines: Clinical inertia or physiological limitations. *JACC Heart Fail.* 8(9):725-738. [https://doi: 10.1016/j.jchf.2020.04.019](https://doi.org/10.1016/j.jchf.2020.04.019)
- Kim, H., Oh, J., Lee, S., Ha, J., Yoon, M., Chun, K. H., *et al.*, 2021. Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis. *Sci. Rep.* 11: 1–8. <https://doi.org/10.1038/s41598-021-95787-w>
- Komajda, K., Lapuerta, P., Hermans, N., Gonzalez-Juanatey, J.R., Veldhuisen, D.J., Erdmann, E., *et al.*, 2005. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. *Eur.J. Heart Fail.* 26(16):1653-9. [https://doi: 10.1093/eurheartj/ehi251](https://doi.org/10.1093/eurheartj/ehi251)
- Lainščak, M., Milinkovic, I., Polovina, M., Crespo-Leiro, M.G., Lund, L.H., *et al.*, 2020. Sex and age related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. *Eur. J. Heart Fail.* 22: 92–102. <https://doi.org/10.1002/ehf.1645>

- Luo, N., Ballew, N.G., O'Brien, E.C., Greiner, M.A., Peterson, P.N., Hammill, B.G., *et al.*, 2018. Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. *Am. Heart J.* 200: 134–140. <https://doi.org/10.1016/j.ahj.2018.01.009>
- Luo, N., Fonarow, G.C., Lippmann, S.J., Mi, X., Heidenreich, P.A., Yancy, C.W., *et al.*, 2017. Early adoption of sacubitril/valsartan for patients with heart failure with reduced ejection fraction: Insights from get with the guidelines heart failure (GWTG-HF). *JACC Hear. Fail.* 5: 305–309. <https://doi.org/10.1016/j.jchf.2016.12.018>
- Maddox, T.M., Januzzi, J.L., Allen, L.A., Breathett, K., Butler, J., Davis, L.L., *et al.*, 2021. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction. *J. Am. Coll. Cardiol.* 77 (6): 772–810. <https://doi.org/10.1016/j.jacc.2020.11.022>
- Mazurek, J.A., Jessup, M., 2005. Understanding Heart Failure. *Card Electrophysiol Clin.* 7(4): 557–575. <https://doi.org/10.1016/j.ccep.2015.08.001>
- McCullough, P.A., Mehta, H.S., Barker, C.M., Houten, J. Van., Mollenkopf, S., *et al.*, 2021. Mortality and guideline-directed medical therapy in real-world heart failure patients with reduced ejection fraction. *Clin. Cardiol.* 4(9): 1192–1198. <https://doi.org/10.1002/clc.23664>
- McDonagh, T.A., Metra, M., Adamo, M., Gardner, R.S., Baumbach, A., Böhm, M., *et al.*, 2021. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur. J. Heart Fail.* 42(36):3599-3726. <https://doi.org/10.1093/eurheartj/ehab368>
- McDonald, M., Virani, S., Chan, M., Ducharme, A., Ezekowitz, J.A., Giannetti, N., Heckman, G.A., Howlett, J.G., Koshman, S.L., Lepage, S., *et al.*, 2021. CCS/CHFS Heart failure guidelines update: Defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. *Can. J. Cardiol.* 37(4):531-546. <https://doi.org/10.1016/j.cjca.2021.01.017>
- McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Böhm, M., Dickstein, K., *et al.*, 2012. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur. J. Heart Fail.* 33(14):1787-1847. <https://doi.org/10.1093/eurheartj/ehs104>
- McMurray, J.J.V., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., *et al.*, 2014. Angiotensin Neprilysin Inhibition versus Enalapril in Heart Failure. *N. Engl. J. Med.* 371: 993–1004. <https://doi.org/10.1056/NEJMoa1409077>

- McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., Kober, L., Kosiborod, M.N., Martinez, F.A., *et al.*, 2019. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N. Engl. J. Med.* 381(21):1995-2008. <https://doi.org/10.1056/NEJMoa1911303>
- Mumpuni, H., Kusumastuti, D.A., Bagaswoto, H.P., Setianto, B.Y., 2021. Epidemiology, aetiology and risk profile of heart failure in a tertiary referral hospital: a Report from the Sardjito heart failure registry. *Acta Cardiol. Indones.* 7: 7–12. <https://doi.org/10.22146/jaci.v7i1>
- Moliner-Abós, C., Rivas-Lasarte, M., Pamies Besora, J., Fluvà-Brugues, P., Solé-González, E., Mirabet, S., *et al.*, 2019. Sacubitril/Valsartan in real life practice: experience in patients with advanced heart failure and systematic review. *Cardiovasc. Drugs Ther.* 33: 307–314. <https://doi.org/10.1007/s10557-019-06858-0>
- Niemiec, R., Morawska, I., Stec, M., Kuczmik, W., Swinarew, A.S., Stanula, A., *et al.*, 2022. ARNI in HFrEF One-Centre Experience in the Era before the 2021 ESC HF Recommendations. *Int. J. Environ. Res. Public Health.* 19: 1–12. <https://doi.org/10.3390/ijerph19042089>
- Okoroike, H., Patel, S., Simone, P., Lavelle, R., Szwak, J.A., 2023. Impact of inpatient initiation of sodium glucose cotransporter 2 inhibitors on prescription rates in patients with heart failure with reduced ejection fraction. *Am. J. Cardiol.* 186:150–155. <https://doi.org/10.1016/j.amjcard.2022.09.019>
- Olofsson, M., Jansson, J.H., Boman, K., 2016. Predictors for hospitalizations in elderly patients with clinical symptoms of heart failure: A 10-year observational primary healthcare study. *J. Clin. Gerontol. Geriatr.* 7: 53–59. <https://doi.org/10.1016/j.jcgg.2015.11.001>
- Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., *et al.*, 2020. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N. Engl. J. Med.* 383(15):1413-1424. <https://doi.org/10.1056/NEJMoa2022190>
- Packer, M., Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J., *et al.*, 2020. Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload EMPEROR-Reduced Trial. *J. Am. Coll. Cardiol.* 77(11):1381-1392. <https://doi.org/10.1016/j.jacc.2021.01.033>
- Parajuli, D.R., Shakib, S., Eng-Frost, J., McKinnon, R.A., Caughey, G. E., Whitehead, D., 2021. Evaluation of the prescribing practice of guideline-directed medical therapy among ambulatory chronic heart failure patients. *BMC Cardiovasc. Disord.* 21(1):104. <https://doi.org/10.1186/s12872-021-01868-z>



- Patil, T., Ali, S., Kaur, A., Akridge, M., Eppes, D., Paarlberg, J., *et al.*, 2022. Impact of pharmacist led heart failure clinic on optimization of guideline directed medical therapy (PHARM-HF). *J. Cardiovasc. Transl. Res.* 15:1424–1435. <https://doi.org/10.1007/s12265-022-10262-9>
- Peri-Okonny, P.A., Mi, X., Khariton, Y., Patel, K.K., Thomas, L., Fonarow, G.C., *et al.*, 2019. Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF registry. *JACC Heart Fail.* 7(4):350-358. <https://doi.org/10.1016/j.jchf.2018.11.011>
- PERKI, 2020. *Pedoman Tatalaksana Gagal Jantung 2020*. 2nd ed., Perhimpunan Dokter Spesialis Kardiovaskular Indonesia.12- 22.
- PIONAS BPOM, 2018. Uperio Tablet salut selaput 50 mg [WWW Document]. URL <http://103.5.148.29/obat-baru/uperio-tablet-salut-selaput-50-mg-243-mg257-mg>
- Polasek, T.M., Kirkpatrick, C.M.J., Rostami-Hodjegan, A., 2019. Precision dosing to avoid adverse drug reactions. *Ther. Adv. Drug Saf.* 10: 2042098619894147. <https://doi.org/10.1177/2042098619894147>
- Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G.F., Coats, A.J.S., Falk, V., *et al.*, 2016. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Kardiol. Pol.* 74: 1037–1147. <https://doi.org/10.5603/KP.2016.0141>
- Prakasa, R.A., Valentina, D.C.D., Abdiana, R., Handayani, R., Irmansyah, N., 2020. Analisis faktor risiko pasien gagal jantung dengan reduced ejection fraction di RSUD Dr. H. Abdul Moeloek Provinsi Lampung. *Essence Sci. Med. J.* 18(1): 22-26. <https://doi.org/10.24843/ESTL.2020.v18.i01.p07>
- Rahajeng, F.T., 2021. Perbandingan Luaran Klinik Penggunaan Kombinasi Sacubitril-Valsartan dengan ARB pada Pasien Gagal Jantung di RSUP Dr. Sardjito Yogyakarta. Universitas Gadjah Mada. <http://etd.repository.ugm.ac.id/penelitian/detail/202792>
- Reyes, E.B., Won Ha, J., Firdaus, S., Ghazi, A.M., Prommintikul, A., Sim, D., *et al.*, 2016. Heart failure across Asia: Same healthcare burden but differences in organization of care. *Int. J. Cardiol.* 223: 163-167. <https://doi.org/10.1016/j.ijcard.2016.07.256>
- Ruppar, T.M., Cooper, P.S., Mehr, D.R., Delgado, J.M., Dunbar-Jacob, J.M., 2016. Medication adherence interventions improve heart failure mortality and readmission rates: Systematic review and meta-analysis of controlled trials. *J. Am. Heart Assoc.* 5: 1–18. <https://doi.org/10.1161/JAHA.115.002606>
- Sangaralingham, L.R., Sangaralingham, S.J., Shah, N.D., Yao, X., Dunlay, S.M., 2018. Adoption of sacubitril/valsartan for the management of patients with heart failure. *Circ. Hear. Fail.* 11: 1–11. <https://doi.org/10.1161/CIRCHEARTFAILURE.117.004302>

- Scalvini, S., Bernocchi, P., Villa, S., Paganoni, A. M., Rovere, M. T. L., Frigerio, M., 2021. Treatment prescription, adherence, and persistence after the first hospitalization for heart failure: A population-based retrospective study on 100785 patients. *Int. J. Cardiol.* 330: 106-111. <https://doi.org/10.1016/j.ijcard.2021.02.016>
- Schwinger, R.H.G., 2021. Pathophysiology of heart failure. *Cardiovasc. Diagn. Ther.* 11(1):263-76. <https://doi.org/10.21037/cdt-20-302>
- Savarese, G., Bodegard, J., Norhammar, A., Sartipy, P., Thuresson, M., Cowie, M.R., *et al.*, 2021. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study. *Eur.J. HeartFail.* 23: 1499-1511. <https://doi.org/10.1002/ehf.2271>
- Seo, W.W., Park, J.J., Ah, T.H., Cho, H.J., Lee H-Y., Kim K.H., *et al.*, 2020. Guideline-directed medical therapy in elderly patients with heart failure with reduced ejection fraction: a cohort study. *BMJ Open.* 10(2): e030514. <https://doi.org/10.1136/bmjopen-2019-030514>
- Sharma, S., Verma, S., Bhatt, D. L., Connelly, K. A., Swiggum, E., Vaduganathan, M., *et al.*, 2022. Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care? *JACC Basic Transl Sci.* 7(5):504-517. <https://doi.org/10.1016/j.jacbs.2021.10.018>
- Srivastava, P., DeVore, A.D., Hellkamp, A.S., Thomas, L., Albert, N. M., Butler, J., *et al.* 2021. Heart failure hospitalization and guideline directed prescribing patterns among heart failure with reduced ejection fraction patients. *JACC Heart Fail.* 9(1):28-38. <https://doi.org/10.1016/j.jchf.2020.08.017>
- Uijl, A., Vaartjes, I., Denaxas, S., Hemingway, H., Shah A., Cleland, J., *et al.*, 2021. Temporal trends in heart failure medication prescription in a population based cohort study. *BMJ Open.* 11: e043290. <http://dx.doi.org/10.1136/bmjopen-2020-043290>
- Verulava, T., Jorbenadze, R., Lordkipanidze, A., Gongadze, A., Tsverava, M., Donjashvili, M., 2021. Readmission after hospitalization for heart failure in elderly patients in Chapidze Emergency Cardiology Center, Georgia. *J. Heal. Res.* 36: 575–583. <https://doi.org/10.1108/JHR-07-2020-0294>
- Virani, S.S., Aparicio, H.J., Benjamin, E.J., Bittencourt, M.S., Callaway, C.W., Carson, A.P., *et al.*, 2021. Heart disease and stroke statistics-2021 Update: a report from the American Heart Association. *Circulation.* 143(8): e245-e743. <https://doi.org/10.1161/CIR.0000000000000950>
- Williams, B., Mancia, G., Spiering, W., Rosei, E.A., Azizi, M., Burnier, M., *et al.*, 2018. ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *Eur. Heart J.* 39 (33): 3021–3104. <https://doi.org/10.1093/eurheartj/ehy339>

- WHO Collaborating Centre for Drug Statistics Methodology, 2022. ATC classification index with DDDs. Oslo, Norwegia.
- Yamaguchi, T., Kitai, T., Miyamoto, T., Kagiya, N., Okumura, T., Kida, K., *et al.*, 2018. Effect of optimizing guideline directed medical therapy before discharge on mortality and heart failure readmission in patients hospitalized with heart failure with reduced ejection fraction. *Am. J. Cardiol.* 121(8): 969–974. [https://doi: 10.1016/j.amjcard.2018.01.006](https://doi.org/10.1016/j.amjcard.2018.01.006)
- Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E., Drazner, M. H., *et al.*, 2013. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. *J. Am. Coll. Cardiol.* 62(16): e147-239. [https://doi: 10.1016/j.jacc.2013.05.019](https://doi.org/10.1016/j.jacc.2013.05.019)
- Young Lee, H., Hee Oh, B., 2020. Paradigm shifts of heart failure therapy: do we need another paradigm. *Int. J. Heart Fail.* 2(3): 145-156. <https://doi.org/10.36628/ijhf.2020.0010>